Metraipolis › archive › dc_e44e38db0e5d

Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study — Europe PMC PMID:41082550

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41082550
DOI
10.1371/journal.pmed.1004499
License (as archived)
solo-consultazione
Archived
2026-11-09T08:44:16.767Z
SHA-256 of the archived text
3b4002b77caca263d3fdd4d659fb4a4967a0c776a2e59f1f5e5a9c7fb5b799f7
Stable URL of this page
https://metraipolis.com/documento/dc_e44e38db0e5d

How to cite

Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study — Europe PMC PMID:41082550 — Europe PMC (en), https://europepmc.org/article/MED/41082550 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e44e38db0e5d (Metraipolis archive dc_e44e38db0e5d, sha256 3b4002b77caca263d3fdd4d659fb4a4967a0c776a2e59f1f5e5a9c7fb5b799f7)
BibTeX
@misc{dce44e38db0e5d,
  title = {Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study — Europe PMC PMID:41082550},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41082550},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e44e38db0e5d; sha256 3b4002b77caca263d3fdd4d659fb4a4967a0c776a2e59f1f5e5a9c7fb5b799f7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41082550. Agents can read the archived copy with the MCP tool read_document.